Cited by 165Cancer-related Molecular PathwaysCell death mechanisms and regulationHeat shock proteins research

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Ambrosini, G, Sambol, E B, Carvajal, D, Vassilev, L T, Singer, S, Schwartz, G K·2007·Oncogene

Open this paper in CoChat — free account

Abstract

MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53-/- cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wild-type E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73alpha and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1-dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210136

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citation
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Expression of transcription factor E2F1 induces quiescent cells to enter S phase
Johnson, D. G., Schwarz, J. K., Cress, W. D., & Nevins, J. R. (1993) · Nature · doi:10.1038/365349a0 · Cited by 943
p53 and E2F-1 cooperate to mediate apoptosis.
Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 840
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.
Qin, X. Q., Livingston, D. M., Kaelin, W. G., & Adams, P. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10918 · Cited by 753
E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosisPreprint
Müller, H., Bracken, A. P., Vernell, R., Moroni, M. C., Christians, F. C., Grassilli, E., Prosperini, E., Vigo, E., Oliner, J. D., & Helin, K. (2001) · Genes & Development · doi:10.1101/gad.864201 · Cited by 752
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M. S., Marín, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citation
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586

Show all 38 references

Research works printed but not linked: 1

Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR . (1998). Role of E2F1 in chemosensitivity. Cancer Res 58: 4292–4296.

Sorted by citations

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Self-citation
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2016) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 612
p53 and E2f: partners in life and death
Polager, S., & Ginsberg, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2718 · Cited by 498
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 372
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & ller, M. M. ⁄. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 309
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 259
Targeting p53 for Novel Anticancer Therapy
Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 256
p53-based Cancer TherapyPreprint
Lane, D. P., Cheok, C. F., & Laı́n, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 251
Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence
Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., Takenoshita, S., Yokota, J., & Harris, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2780 · Cited by 231
Tumour suppression by p53: the importance of apoptosis and cellular senescence
Zuckerman, V., Wolyniec, K., Sionov, R. V., Haupt, S., & Haupt, Y. (2009) · The Journal of Pathology · doi:10.1002/path.2584 · Cited by 222
Liposarcomas: diagnostic pitfalls and new insights
Tos, A. P. D. (2013) · Histopathology · doi:10.1111/his.12311 · Cited by 207
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 198
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer
Crijns, A. P. G., Fehrmann, R. S. N., de Jong, S., Gerbens, F., Meersma, G. J., Klip, H. G., Hollema, H., Hofstra, R. M. W., Meerman, G. J. T., de Vries, E. G. E., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000024 · Cited by 175
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Functional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170
Self-citation
Proteasome system of protein degradation and processing
Sorokin, A. V., Kim, E. R., & Ovchinnikov, L. P. (2009) · Biochemistry (Moscow) · doi:10.1134/s000629790913001x · Cited by 163
p53‐repressed miRNAs are involved with E2F in a feed‐forward loop promoting proliferation
Brosh, R., Shalgi, R., Liran, A., Landan, G., Korotayev, K., Nguyen, G. H., Enerly, E., Johnsen, H., Buganim, Y., Solomon, H., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.65 · Cited by 153
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 156
Resistance mechanisms to cancer chemotherapy
Redmond, K. M. (2008) · Frontiers in bioscience · doi:10.2741/3070 · Cited by 150
Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Shen, H., & Maki, C. G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 148
Opportunities for improving the therapeutic ratio for patients with sarcoma
Wunder, J. S., Nielsen, T. O., Maki, R. G., O’Sullivan, B., & Alman, B. A. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70169-9 · Cited by 144
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Self-citation
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
Liu, Y., Wang, X., Wang, G., Yang, Y., Yuan, Y., & Ouyang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.018 · Cited by 133
Molecular Basis for the Inhibition of p53 by Mdmx
Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131
The roles and regulation of MDM2 and MDMX: it is not just about p53Preprint
Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. L. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 138
Small molecular weight protein–protein interaction antagonists—an insurmountable challenge?
Dömling, A. S. S. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.04.603 · Cited by 128
p53-Independent Roles of MDM2 in NF-κB Signaling: Implications for Cancer Therapy, Wound Healing, and Autoimmune Diseases
Thomasová, D., Mulay, S. R., Bruns, H., & Anders, H. (2012) · Neoplasia · doi:10.1593/neo.121534 · Cited by 126
Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
Maerken, T. V., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J. J., Cuvelier, C. A., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp355 · Cited by 120
Chemotherapy and signaling
Bagnyukova, T., Serebriiskii, I. G., Zhou, Y., Hopper-Borge, E. A., Golemis, E. A., & Astsaturov, I. A. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.9.13738 · Cited by 122
Targeting p53 by small molecules in hematological malignancies
Saha, M. N., Qiu, L., & Chang, H. H. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-23 · Cited by 112
CK1α Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability
Huart, A.-S., MacLaine, N. J., Meek, D. W., & Hupp, T. R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052647 · Cited by 110
Reversal of P-glycoprotein–Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
Michaelis, M., Rothweiler, F., Klassert, D., von Deimling, A., Riecken, K., Fehse, B., Kammerer, B., Doerr, H. W., & Cinatl, J. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1856 · Cited by 101
Preeclampsia Is Associated with Alterations in the p53-Pathway in Villous Trophoblast
Sharp, A. N., Heazell, A. E. P., Baczyk, D., Dunk, C., Lacey, H. A., Jones, C. J. P., Perkins, J., Kingdom, J. C., Baker, P. N., & Crocker, I. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087621 · Cited by 98
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 101
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95
p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma
Roh, J., Kang, S. K., Minn, I., Califano, J. A., Sidransky, D., & Koch, W. M. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.10.011 · Cited by 92
Roles for CSN5 in control of p53/MDM2 activities
Zhang, X., Chen, J., Su, C., Yang, H.-Y., & Lee, M. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21504 · Cited by 88
E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines
Kitagawa, M., Aonuma, M., Lee, S. H., Fukutake, S., & McCormick, F. P. (2008) · Oncogene · doi:10.1038/onc.2008.164 · Cited by 89
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 86
Effects of wound dressing based on the combination of silver@curcumin nanoparticles and electrospun chitosan nanofibers on wound healing
Liu, C., Zhu, Y., Lun, X., Sheng, H., & Yan, A. (2022) · Bioengineered · doi:10.1080/21655979.2022.2031415 · Cited by 85
Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions
Gopal, Y. N. V., Chanchorn, E., & Dyke, M. W. V. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0661 · Cited by 83
The E2F family and the role of E2F1 in apoptosis
Wu, Z., Zheng, S., & Yu, Q. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.06.004 · Cited by 86
p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells
Periyasamy, M., Singh, A. K., Gemma, C., Kranjec, C., Farzan, R. A., Leach, D. A., Navaratnam, N., Pálinkás, H. L., Vértessy, B. G., Fenton, T. R., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx721 · Cited by 79
The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 80
Self-citation
Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis
Dongiovanni, P., Fracanzani, A. L., Cairo, G., Megazzini, C., Gatti, S., Rametta, R., Fargion, S. R., & Valenti, L. V. C. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090249 · Cited by 72
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
Supiot, S., Hill, R. P., & Bristow, R. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0442 · Cited by 74
The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
Deben, C., Wouters, A., de Beeck, K. O., van Den Bossche, J., Jacobs, J., Zwaenepoel, K., Peeters, M., Van Meerbeeck, J., Lardon, F., Rolfo, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4433 · Cited by 73
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
Drakos, E., Singh, R. R., Rassidakis, G. Z., Schlette, E. J., Li, J., Claret, F. X., Ford, R. J., Vega, F., & Medeiros, L. J. (2011) · Leukemia · doi:10.1038/leu.2011.28 · Cited by 67
The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73
Peirce (2009) · International Journal of Oncology · doi:10.3892/ijo_00000267 · Cited by 67
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 72
Murine double minute 2: p53-independent roads lead to genome instability or death
Bouska, A. C., & Eischen, C. M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.02.006 · Cited by 68
Translating DNA damage into cancer cell death—A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance
Engelmann, D., & Pützer, B. M. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.06.001 · Cited by 69
Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma
Zheng, T., Yin, D., Lu, Z., Wang, J., Li, Y., Chen, X., Liang, Y., Song, X., Qi, S., Sun, B., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-133 · Cited by 60
Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia
Vilas‐Zornoza, A., Agirre, X., Martín‐Palanco, V., Martín-Subero, J. I., José‐Eneriz, E. S., Gárate, L., Álvarez, S., Miranda, E., Rodríguez‐Otero, P., Rifón, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017012 · Cited by 58
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts
Alhosin, M., Ibrahim, A., Boukhari, A., Sharif, T., Gies, J., Auger, C., & Schini‐Kerth, V. B. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9734-1 · Cited by 60
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Vena, F., Causi, E. L., Rodriguez‐Justo, M., Goodstal, S. M., Hagemann, T., Hartley, J. A., & Hochhauser, D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0485 · Cited by 56
MDM2 Inhibitor Nutlin-3a Induces Apoptosis and Senescence in Cutaneous T-Cell Lymphoma: Role of p53
Manfé, V., Biskup, E., Johansen, P., Kamstrup, M. R., Krejsgaard, T., Morling, N., Wulf, H. C., & Gniadecki, R. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.10 · Cited by 51
Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist
Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152513 · Cited by 49
MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53
Klein, A. M., Biderman, L., Tong, D., Alaghebandan, B., Plumber, S. A., Mueller, H. S., van Vlimmeren, A. E., Katz, C., & Prives, C. L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102420118 · Cited by 48
HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA
Rinaldo, C., Prodosmo, A., Siepi, F., Moncada, A., Sacchi, A., Selivanova, G., & Soddu, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0337 · Cited by 48
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
Maerken, T. V., Rihani, A., Goethem, A. V., Paepe, A. D., Speleman, F., & Vandesompele, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.002 · Cited by 47
The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts
Secchiero, P., Zerbinati, C., Melloni, E., Milani, D., Campioni, D., Fadda, R., Tiribelli, M., & Zauli, G. (2007) · Neoplasia · doi:10.1593/neo.07523 · Cited by 47
MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro
Wang, J., Zheng, T., Chen, X., Song, X., Meng, X., Bhatta, N., Pan, S., Jiang, H., & Liu, L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06440.x · Cited by 45
MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Barone, G., Tweddle, D. A., Shohet, J. M., Chesler, L., Moreno, L., Pearson, A. D. J., & Maerken, T. V. (2014) · Current Drug Targets · doi:10.2174/13894501113149990194 · Cited by 45
Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells
Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W., & Giardina, C. A. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20795 · Cited by 45
The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53
Drakos, E., Atsaves, V., Schlette, E. J., Li, J.-D., Papanastasi, E., Rassidakis, G. Z., & Medeiros, L. J. (2009) · Leukemia · doi:10.1038/leu.2009.180 · Cited by 44
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 44
Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma
Gross, N. D., Boyle, J. O., Du, B., Kekatpure, V. D., Lantowski, A., Thaler, H. T., Weksler, B. B., Subbaramaiah, K., & Dannenberg, A. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0352 · Cited by 44
Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells
Sonnemann, J., Palani, C. D., Wittig, S., Becker, S., Eichhorn, F., Voigt, A., & Beck, J. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.015 · Cited by 43
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
Chen, L., Zhao, Y., Halliday, G. C., Berry, P., Rousseau, R. F., Middleton, S. A., NICHOLS, G. L., Bello, F. D., Piergentili, A., Newell, D. R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.325 · Cited by 43
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
Chen, L., & Tweddle, D. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00173 · Cited by 43
Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
The Role of MDM2 in Promoting Genome Stability versus Instability
Saadatzadeh, M. R., Elmi, A. N., Pandya, P. H., Bijangi‐Vishehsaraei, K., Ding, J., Stamatkin, C. W., Cohen‐Gadol, A., & Pollok, K. E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102216 · Cited by 44
Characterization of Liposarcoma Cell Lines for Preclinical and Biological Studies
Stratford, E. W., Castro, R., Daffinrud, J., Skårn, M., Lauvrak, S. U., Munthe, E., & Myklebost, O. (2012) · Sarcoma · doi:10.1155/2012/148614 · Cited by 40
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention
Peirce, S. K., Findley, H. W., Prince, C. Z., Dasgupta, A., Cooper, T. M., & Durden, D. L. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1486-7 · Cited by 39
p73 as a Pharmaceutical Target for Cancer Therapy
Bisso, A., Collavin, L., & Sal, G. D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222667 · Cited by 41
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
Haaland, I., Opsahl, J. A., Berven, F. S., Reikvam, H., Fredly, H., Haugse, R., Thiede, B., McCormack, E., Laı́n, S., Bruserud, Ø., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-116 · Cited by 36
Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
Alaseem, A. M. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101790 · Cited by 36
Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins
Hiss, D. C., & Gabriels, G. A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903052559 · Cited by 35
Nutlin-3 Affects Expression and Function of Retinoblastoma Protein
Du, W., Wu, J., Walsh, E. M., Zhang, Y., Chen, C. Y., & Xiao, Z.-X. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046904 · Cited by 33
Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma
Jones, R. J., Chen, Q., Voorhees, P. M., Young, K. H., Bruey-Sédano, N., Yang, D., & Orlowski, R. Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0150 · Cited by 31
Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53–induced apoptosis
Nakamizo, A., Amano, T., Zhang, W., Zhang, X.-Q., Ramdas, L., Liu, T.-J., Bekele, B. N., Shono, T., Sasaki, T., Benedict, W. F., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-015 · Cited by 32
Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells
Carrillo, A. M., Hicks, M., Khabele, D., & Eischen, C. M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0089 · Cited by 31
p73: From the p53 shadow to a major pharmacological target in anticancer therapy
Ramos, H., Raimundo, L., & Saraiva, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105245 · Cited by 33
Resistance acquisition to MDM2 inhibitors
Cinatl, J., Speidel, D., Hardcastle, I., & Michaelis, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140035 · Cited by 30
E2F1-dependent oncogenic addiction of melanoma cells to MDM2
Verhaegen, M. E., Chęcińska, A., Riblett, M., Wang, S., & Soengas, M. S. (2011) · Oncogene · doi:10.1038/onc.2011.277 · Cited by 31
Novel p53 therapies for head and neck cancer
Castellanos, M. R., & Pan, Q. (2016) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1016/j.wjorl.2016.05.005 · Cited by 30
Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Zanjirband, M., & Rahgozar, S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402120701 · Cited by 31
Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein–Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells
Renouf, B., Hollville, É., Pujals, A., Tétaud, C., Garibal, J., & Wiels, J. (2009) · Leukemia · doi:10.1038/leu.2009.92 · Cited by 32
An iTRAQ Proteomics Screen Reveals the Effects of the MDM2 Binding Ligand Nutlin-3 on Cellular Proteostasis
Nicholson, J., Neelagandan, K. S., Huart, A.-S., Ball, K. L., Molloy, M. P., & Hupp, T. R. (2012) · Journal of Proteome Research · doi:10.1021/pr300698d · Cited by 28
Targeted Therapies in Bone Sarcomas
Scotlandi, K., Picci, P., & Kovar, H. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789760410 · Cited by 26
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
Sui, X., Shin, S., Zhang, R., Firozi, P. F., Yang, L., Abbruzzese, J. L., & Reddy, S. A. G. (2009) · Oncogene · doi:10.1038/onc.2008.423 · Cited by 25
Heavy ion radiation-induced DNA damage mediates apoptosis via the Rpl27a-Rpl5-MDM2-p53/E2F1 signaling pathway in mouse spermatogonia
Li, H., Zhang, H., Huang, G., Dou, Z., Xie, Y., Si, J., & Di, C. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110831 · Cited by 24
Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic
Al-Hussaini, M., & DiPersio, J. F. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.932687 · Cited by 26
2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway
Xu, J., Han, M., Shen, J., Guan, Q., Bai, Z., Lang, B., Zhang, H., Li, Z., Zuo, D., Zhang, W., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.011 · Cited by 24

Authors: Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Schwartz, G K
ORCID: Ambrosini, G
Vassilev, L T
Singer, S
Schwartz, G K
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2006-12-04
Volume: 26
Issue: 24
Pages: 3473-3481
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210136
OpenAlex: W2003463790
Cited by: 163
References: 38
Citations by year: 2026: 1 · 2025: 2 · 2024: 2 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 7 · 2018: 1 · 2017: 8 · 2016: 5 · 2015: 6 · 2014: 13 · 2013: 11 · 2012: 15
FWCI: 7.59
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: Nutlin-3a, MDM2 inhibitors, mutant p53, E2F1, chemotherapy-induced apoptosis, cisplatin, chemosensitization, malignant peripheral nerve sheath tumor, liposarcoma, p73alpha, Noxa, proteasomal degradation, p53-MDM2 interaction, doxorubicin, carboplatin
MeSH terms: Tumor Protein p73, Animals, Antineoplastic Agents, Cisplatin, DNA-Binding Proteins, Doxorubicin, Humans, Imidazoles, Nuclear Proteins, Piperazines, Transcription, Genetic, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Carboplatin, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Tumor Suppressor Proteins, E2F1 Transcription Factor, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks